Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

New Application Note Addresses Benefits of aCGH/SNP Cancer Research Arrays

By BiotechDaily International staff writers
Posted on 10 Apr 2013
Image: CytoSure Cancer +SNP arrays from Oxford Gene Technology (Photo courtesy of Oxford Gene Technology.)
Image: CytoSure Cancer +SNP arrays from Oxford Gene Technology (Photo courtesy of Oxford Gene Technology.)
A new application note on combined array comparative genomic hybridization (aCGH) and single nucleotide polymorphism (SNP) arrays is now available to support researchers in navigating the combined approach for the simultaneous detection of copy number variations (CNVs) and runs of homozygosity (ROH).

The application note, titled “Detecting copy number variants and runs of homozygosity on a single array — challenges and applications” is provided by Oxford Gene Technology (OGT; Oxfordshire, UK). aCGH has been established as the “gold-standard” platform for array-based CNV detection. Recent advances have enabled the combination of aCGH probes for CNV detection with probes able to detect SNPs. Particularly well suited for clinical genetics researchers, the application note highlights the importance and benefits of these combined probe arrays in the detection of various genetic conditions. For example, OGT’s CytoSure aCGH +SNP arrays allow any reference DNA to be used and no restriction digest of the sample is required. This enables labeling and hybridization steps to be completed in a single day (unlike typical SNP platforms) while providing information on changes in copy number and regions of homozygosity, and integrating into existing workflows.

The OGT arrays have been research-validated to provide informative, biologically relevant SNP data for various genetic aberrations such as uniparental disomy (UDP), mosaic aneuploidy and ROH, without compromising on high-quality CNV data. CytoSure aCGH +SNP arrays are available for constitutional, cancer, and molecular genetics research. Each array also comes with complimentary access to OGT’s “CytoSure Interpret Software,” a powerful, user-friendly CNV and SNP data analysis package, which contains innovative features to minimize user intervention and maximize consistency and speed of data interpretation.

Related Links:
Oxford Gene Technology
Application note


Channels

Genomics/Proteomics

view channel
Image: Pulsed near infrared light (shown in red) is shone onto a tumor (shown in white) that is encased in blood vessels. The tumor is imaged by photoacoustic tomography via the ultrasound emission (shown in blue) from the gold nanotubes (Photo courtesy of Jing Claussen (iThera Medical, Germany)).

Gold Nanotubes Are Novel Agents for Cancer Diagnosis and Treatment

Cancer researchers have produced a highly defined class of gold nanotubes that are suitable for use in animals as in vivo imaging nanoprobes, photothermal conversion agents, and drug delivery vehicles.... Read more

Drug Discovery

view channel
Image: Molecular model of the protein Saposin C (Photo courtesy of Wikimedia Commons).

Nanovesicles Kill Human Lung Cancer Cells in Culture and in a Mouse Xenograft Model

Nanovesicles assembled from the protein Saposin C (SapC) and the phospholipid dioleoylphosphatidylserine (DOPS) were shown to be potent inhibitors of lung cancer cells in culture and in a mouse xenograft model.... Read more

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Business

view channel

Roche Acquires Signature Diagnostics to Advance Translational Research

Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays. Signature Diagnostics is a privately held translational oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.